INDUSTRY NEWS
NICE GUIDANCE WELCOMED
Allergan plc has welcomed the publication of NICE guidance recommending the use of OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) for an important group of patients with diabetic macular oedema (DME).
“This guidance from NICE confirms the value of OZURDEX® as a treatment for DME, and supports its use as a clinically relevant and cost effective option for patients with this condition,†said Sara Vincent, Senior Vice President and Allergan UK Country Manager. www.allergan.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.